The Best Psychedelic for Addiction? Comparing Ibogaine, Psilocybin, Ketamine, Ayahuasca

Why “Which Psychedelic Is Best for Addiction?” Is the Wrong First Question

People arrive at this question having already read a few headlines. One promises that a single ibogaine session ends opioid dependence. Another reports that psilocybin cut heavy drinking days in half. The headlines are not wrong, but they are answering different questions, and comparing them side by side without accounting for what each one actually studied leads people to the wrong conclusion.

The useful framing is narrower. Rather than asking which is the best psychedelic for addiction in the abstract, ask which compound has been tested against the specific substance you are trying to stop, in what kind of study, and at what level of risk. Alcohol, tobacco, opioids, and stimulants are pharmacologically distinct problems with distinct research literatures. A finding in one does not transfer cleanly to another.

What follows is a comparison of the four compounds most often discussed, ordered by how much evidence actually stands behind each, and paired with what each one demands in terms of medical supervision.

Psilocybin: The Strongest Controlled Evidence, Mostly for Alcohol and Tobacco

Psilocybin has the most credible randomized data of any classic psychedelic in the addiction space, and it is concentrated in two areas.

For alcohol use disorder, a double-blind randomized trial published in JAMA Psychiatry in 2022 assigned 93 participants to either two high-dose psilocybin sessions or an active placebo, both alongside twelve weeks of structured psychotherapy. The percentage of heavy drinking days over the following 32 weeks was significantly lower in the psilocybin group. This is a genuinely strong result by the standards of addiction medicine, where durable effects are rare, but it is one trial, and psychotherapy was delivered to both arms. The medicine did not work alone.

For tobacco, the picture recently improved. Early work at Johns Hopkins was an open-label pilot with only fifteen smokers, and while the abstinence figures were remarkable, an uncontrolled study of that size cannot carry much weight. In 2026, the same group published a pilot randomized trial in JAMA Network Open comparing psilocybin plus cognitive behavioral therapy against a nicotine patch plus the same therapy. At six months, biochemically verified prolonged abstinence was roughly 40 percent in the psilocybin group compared to 10 percent with the patch. That is now a controlled comparison against an established treatment, which is a meaningfully different class of evidence.

Two limitations matter. Psilocybin remains a Schedule I substance federally in the United States, with legal supported access available only through Oregon‘s and Colorado‘s regulated programs or through clinical trials. And the trials that produced these results were medicine plus a structured therapeutic protocol, which is why the preparation and integration work around the session is not an option.

Ketamine: Legally Available Today, With Real but Narrower Data

Ketamine occupies a strange position. It has less addiction-specific evidence than psilocybin, but it is the only one of these four compounds you can legally access under medical supervision in nearly every U.S. state right now.

The most important trial is KARE, published in the American Journal of Psychiatry in 2022. It randomized 96 patients with severe alcohol use disorder across four conditions, combining ketamine or saline infusions with either relapse-prevention therapy or alcohol education. Participants who received ketamine plus therapy stayed abstinent for the large majority of the six-month follow-up, significantly more days than the placebo group, and the trial was well tolerated with no serious adverse events linked to the drug.

The caveats are real. The confidence intervals were wide, consistent with a proof-of-concept study rather than a definitive one. And ketamine carries something none of the classic psychedelics do: a genuine potential for misuse. It has recreational demand and a documented dependency profile of its own. For someone with a history of compulsive substance use, that is not a footnote. It is a reason why unsupervised or loosely supervised at-home ketamine is a particularly poor fit for addiction work, even though it is widely marketed.

Ketamine’s practical advantage is access. Its practical disadvantage is that the effects tend to be shorter-lived than a full psilocybin session, and maintaining them usually means repeat infusions and sustained therapeutic support. For a fuller comparison of how these two compounds differ mechanically, see our breakdown of what the research actually says about psilocybin versus ketamine.

Ibogaine: The Most Dramatic Signal and the Most Serious Risk

Ibogaine is the compound people ask about when the problem is opioids. Observational reports consistently describe something no other treatment produces: a rapid collapse of withdrawal symptoms and craving after a single administration, sometimes lasting months.

Here is where the evidence stands. There are no randomized placebo-controlled trials of ibogaine for opioid use disorder. None. The entire human evidence base consists of open-label observational studies, retrospective analyses, and case reports. The largest published dataset comes from a fee-for-service clinic in St. Kitts operated by researcher Deborah Mash, covering 191 patients with cocaine and opioid dependence, where oral doses were reported as well tolerated with reduced craving. A twelve-month observational follow-up in New Zealand reported durable reductions in opioid use for a subset of participants. These are consistent signals. They are not proof.

The risk is that Ibogaine prolongs the QT interval on an electrocardiogram, which can trigger Torsades De Pointes, a potentially fatal ventricular arrhythmia. This is not a theoretical concern extrapolated from animal data. Deaths have occurred. A closely monitored Dutch study of fourteen opioid-dependent patients found that half developed a QTc interval above 500 milliseconds, the threshold cardiologists treat as dangerous, though all normalized eventually under supervision. Metabolism varies enormously between individuals depending on CYP2D6 genotype, meaning the same dose produces very different blood levels in different people.

Reviews of ibogaine fatalities find they cluster around a recognizable pattern: preexisting cardiovascular disease, concurrent use of opioids or benzodiazepines, and absent or inadequate cardiac screening beforehand. In settings with continuous ECG telemetry, genotyping, and magnesium protocols, the transient QT prolongation has been managed without deaths. In unregulated clinics abroad, where much ibogaine treatment actually happens, none of that infrastructure is guaranteed.

Our read is that ibogaine may eventually earn a place in opioid treatment, and federal and state interest has accelerated toward funding the trials that would settle the question. Today, anyone considering it should treat cardiac screening and continuous monitoring as absolute preconditions, not preferences. The most recent ibogaine research and the state of the safety debate is worth reading in full before making a decision.

Ayahuasca: The Weakest Evidence Base of the Four

Ayahuasca has a long ceremonial history of use in contexts where substance dependence was addressed, and that history is genuinely meaningful. It is not, however, a substitute for clinical data, and the clinical data here is thin.

The most cited study is a 2013 preliminary observational report from a rural First Nations community in British Columbia, where participants took part in retreats combining four days of group counselling with two ayahuasca ceremonies. Self-reported alcohol, tobacco, and cocaine use declined, and the reduction in problematic cocaine use reached statistical significance. Cannabis and opiate use did not decline. The sample was small, there was no control group, and the outcomes were self-reported.

That is essentially the state of the field. Qualitative interview studies point in a similar direction, but there is no randomized controlled trial of ayahuasca for any substance use disorder.

There is a further consideration specific to ayahuasca. The brew contains monoamine oxidase inhibitors, which interact dangerously with SSRIs and a long list of other medications. Since many people with addiction histories are also on antidepressants, this is a screening issue that comes up constantly.

How the Four Compare at a Glance

• Alcohol use disorder: Psilocybin has the strongest randomized evidence. Ketamine has credible randomized evidence and is legally accessible now. Both were paired with therapy in the trials that worked.
• Tobacco: Psilocybin is the only one of the four with a controlled trial beating an established treatment.
• Opioids: Ibogaine has the most striking signal and the least rigorous evidence, plus a cardiac risk profile that requires medical infrastructure most providers do not have.
• Stimulants: The evidence is thinnest across the board. Ayahuasca’s cocaine finding and ibogaine’s observational data are the main entries, and neither is strong.

One pattern runs through every positive result above. In each trial that produced durable change, the medicine was embedded inside a structured psychological protocol. Ketamine worked alongside relapse-prevention therapy and not alongside alcohol education. The compound appears to create a window of openness, and what happens inside that window determines whether anything changes.

What Should Actually Guide the Decision?

Start with the substance. If alcohol is the problem, psilocybin and ketamine are the two with real trial data behind them, and ketamine is the one you can access legally in most places today. If tobacco is the problem, psilocybin is the only compound with a controlled comparison. If opioids are the problem, the honest answer is that ibogaine carries both the most compelling anecdotal signal and a mortality risk that demands cardiac clearance and continuous monitoring, and that established treatments like buprenorphine still have far more evidence behind them.

Then look at your own medical picture. Cardiac history rules out ibogaine in most cases. A personal or family history of psychosis or bipolar disorder complicates every classic psychedelic on this list. SSRI use is a live issue for ayahuasca and requires careful planning with psilocybin. These are not paperwork exercises. A full review of the medical conditions and medications that should prompt a pause is the right place to start, ideally before you have settled on a compound at all.

Finally, consider the therapeutic structure on offer. Any provider who presents the medicine as the whole intervention is describing something the research does not support. The trials that produced durable results all wrapped the session in preparation, therapy, and integration. If that scaffolding is missing, the evidence you read about does not apply to what you would be doing.

Addiction is one of the areas where psychedelic research is most promising and also where the gap between what people believe and what has been demonstrated is widest. The right compound depends on the substance, your medical history, what is legally accessible where you are, and what kind of support surrounds the experience.